DR. REDDY'S LABORATORIES-ADR (RDY) Stock Price, Quote, News and Overview
NYSE:RDY - New York Stock Exchange, Inc. - US2561352038 - ADR - Currency: USD
RDY Quote, Performance and Key Statistics
DR. REDDY'S LABORATORIES-ADR
NYSE:RDY (1/29/2025, 8:04:00 PM)
After market: 13.52 0 (0%)13.52
-0.01 (-0.07%)
The current stock price of RDY is 13.52 USD. In the past month the price decreased by -14.75%. In the past year, price decreased by -6.36%.
RDY Latest News, Press Releases and Analysis
Dr Reddy's Laboratories Q3 Earnings: Double-Digit Growth Aided By Newly Acquired Nicotine Replacement Business
Dr. Reddy's Q3 FY2025 revenue reached $977 million, up 16%, with $165M net income. Growth fueled by NRT portfolio and global generics expansion.
Dr. Reddy’s Q3 & 9MFY25 Financial Results
Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market
Dr. Reddy’s Q2 & H1FY25 Financial Results
RDY Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 79.06 | 763.33B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 28.29 | 373.21B | ||
| JNJ | JOHNSON & JOHNSON | 15.13 | 363.91B | ||
| MRK | MERCK & CO. INC. | 16.52 | 248.61B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.44 | 217.85B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.8 | 205.78B | ||
| PFE | PFIZER INC | 10.32 | 150.86B | ||
| SNY | SANOFI-ADR | 12.51 | 130.75B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 50.47 | 119.76B | ||
| ZTS | ZOETIS INC | 29.55 | 76.80B | ||
| GSK | GSK PLC-SPON ADR | 8.47 | 71.53B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 22.18 | 42.20B |
Related stock screener links
About RDY
Company Profile
Dr Reddy's Laboratories Ltd is a IN-based company operating in Pharmaceuticals industry. The company is headquartered in Hyderabad, Telangana and currently employs 26,343 full-time employees. Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. The company works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
Company Info
DR. REDDY'S LABORATORIES-ADR
8-2-337, Road No.3 Banjara Hills
Hyderabad TELANGANA 500-034 IN
CEO: Erez Israeli
Employees: 27048
Company Website: https://www.drreddys.com/
Investor Relations: https://www.drreddys.com/investors.aspx
Phone: 914049002900
RDY FAQ
What is the stock price of RDY?
The current stock price of RDY is 13.52 USD.
What is the symbol for DR. REDDY'S LABORATORIES-ADR stock?
The exchange symbol of DR. REDDY'S LABORATORIES-ADR is RDY and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is RDY stock listed?
RDY stock is listed on the New York Stock Exchange, Inc. exchange.
Is RDY a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for RDY, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of RDY.
Does RDY stock pay dividends?
RDY has a dividend yield of 0.68%. The yearly dividend amount is currently 7.99.
What is the Price/Earnings (PE) ratio of RDY?
The PE ratio for RDY is 18.27. This is based on the reported non-GAAP earnings per share of 0.74 and the current share price of 13.52 USD.
What is the Short Interest ratio of RDY stock?
The outstanding short interest for RDY is 2.23% of its float.
RDY Technical Analysis
RDY Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to RDY. While RDY has a great profitability rating, there are some minor concerns on its financial health.
RDY Financial Highlights
Over the last trailing twelve months RDY reported a non-GAAP Earnings per Share(EPS) of 0.74. The EPS decreased by 2.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 17.75% | ||
| ROA | 11.43% | ||
| ROE | 17.36% | ||
| Debt/Equity | 0.02 |
RDY Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 57% to RDY. The Buy consensus is the average rating of analysts ratings from 42 analysts.
For the next year, analysts expect an EPS growth of 1.89% and a revenue growth 15.32% for RDY